Aliases & Classifications for Aphasia

MalaCards integrated aliases for Aphasia:

Name: Aphasia 12 51 29 52 41 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0060046

Summaries for Aphasia

NINDS : 51 Aphasia is a neurological disorder caused by damage to the portions of the brain that are responsible for language production or processing.  It may occur suddenly or progressively, depending on the type and location of brain tissue involved.  Primary signs of the disorder include difficulty in expressing oneself when speaking, trouble understanding speech, and difficulty with reading and writing. Aphasia is not a disease, but a symptom of brain damage. Although it is primarily seen in individuals who have suffered a stroke, aphasia can also result from a brain tumor, infection, inflammation, head injury, or dementia that affect language-associated regions of the brain. It is estimated that about 1 million people in the United States today suffer from aphasia. The type and severity of language dysfunction depends on the precise location and extent of the damaged brain tissue. Generally, aphasia can be divided into four broad categories: (1) Expressive aphasia (also called Broca's aphasia) involves difficulty in conveying thoughts through speech or writing. The person knows what she/he wants to say, but cannot find the words he needs. (2) Receptive aphasia (Wernicke's aphasia) involves difficulty understanding spoken or written language. The individual hears the voice or sees the print but cannot make sense of the words. (3) Global aphasia results from severe and extensive damage to the language areas of the brain.  People lose almost all language function, both comprehension and expression. They cannot speak or understand speech, nor can they read or write.  (4) Indiivfduals withanomic or amnesia aphasia, the least severe form of aphasia, have difficulty in using the correct names for particular objects, people, places, or events.

MalaCards based summary : Aphasia is related to autotopagnosia and pervasive developmental disorder, and has symptoms including back pain, cachexia and cyanosis. An important gene associated with Aphasia is L1CAM (L1 Cell Adhesion Molecule), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Neuroscience. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and cellular

MedlinePlus : 41 aphasia is a disorder caused by damage to the parts of the brain that control language. it can make it hard for you to read, write, and say what you mean to say. it is most common in adults who have had a stroke. brain tumors, infections, injuries, and dementia can also cause it. the type of problem you have and how bad it is depends on which part of your brain is damaged and how much damage there is. there are four main types: expressive aphasia - you know what you want to say, but you have trouble saying or writing what you mean receptive aphasia - you hear the voice or see the print, but you can't make sense of the words anomic aphasia - you have trouble using the correct word for objects, places, or events global aphasia - you can't speak, understand speech, read, or write some people recover from aphasia without treatment. most, however, need language therapy as soon as possible. nih: national institute of neurological disorders and stroke

Disease Ontology : 12 A language disorder that involves an acquired impairment of any laguage modality such as producting or comprehending spoken or written language.

Wikipedia : 72 Aphasia is an inability to comprehend and formulate language because of damage to specific brain... more...

Related Diseases for Aphasia

Diseases related to Aphasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 183)
id Related Disease Score Top Affiliating Genes
1 autotopagnosia 30.1 GRN PSEN1
2 pervasive developmental disorder 29.3 FOXP2 GRN PSEN1
3 akinetic mutism 29.2 APOE APP GRN PSEN1
4 auditory agnosia 28.9 APOE C9orf72 FOXP2 GRN MAPT
5 pick disease 27.7 APOE APP C9orf72 CHMP2B GRN LRRK2
6 epilepsy-aphasia spectrum 12.3
7 logopenic progressive aphasia 12.3
8 nominal aphasia 12.2
9 progressive non-fluent aphasia 12.2
10 landau-kleffner syndrome 11.8
11 epilepsy, focal, with speech disorder and with or without mental retardation 11.7
12 progressive supranuclear palsy-progressive non-fluent aphasia syndrome 11.7
13 intellectual disability-expressive aphasia-facial dysmorphism syndrome 11.7
14 frontotemporal lobar degeneration with ubiquitin-positive inclusions 11.7
15 semantic dementia 11.6
16 masa syndrome 11.6
17 gerstmann syndrome 11.5
18 dementia, frontotemporal 11.4
19 cerebral atrophy 11.3
20 apraxia 11.1
21 agraphia 11.0
22 moyamoya disease 11.0
23 marchiafava bignami disease 11.0
24 autosomal dominant partial epilepsy with auditory features 10.8
25 spastic paraplegia 1 10.7
26 acquired purpura fulminans 10.7 APOE MAPT
27 handl syndrome 10.7
28 myelinoclastic diffuse sclerosis 10.7
29 inclusion body myopathy with early-onset paget disease and frontotemporal dementia 10.7
30 progressive multifocal leukoencephalopathy 10.7
31 sudanophilic cerebral sclerosis 10.7
32 dementia, familial, nonspecific 10.7
33 transient cerebral ischemia 10.7
34 supranuclear palsy, progressive 10.7
35 mini stroke 10.7
36 hfe-associated hereditary hemochromatosis 10.6 APOE PRNP
37 ceroid lipofuscinosis, neuronal, 11 10.6 GRN MAPT
38 simultanagnosia 10.6 GRN PSEN1
39 penis basal cell carcinoma 10.5 MAPT PRNP
40 extraosseous ewings sarcoma-primitive neuroepithelial tumor 10.5 GRN PSEN1
41 hyperglycemia 10.5 CHMP2B GRN
42 autoimmune disease of urogenital tract 10.5 GRN PSEN1
43 seow najjar syndrome 10.5 APOE GRN MAPT
44 dementia 10.4
45 ectodermal dysplasia alopecia preaxial polydactyly 10.4 APP PSEN1
46 urethritis 10.4 APOE PSEN1
47 cervical squamous cell carcinoma 10.4 APP PRNP
48 glucose metabolism disease 10.4 GRN PSEN1
49 pulmonary systemic sclerosis 10.4 APOE APP MAPT
50 bladder cancer, childhood 10.4 APOE APP MAPT

Graphical network of the top 20 diseases related to Aphasia:



Diseases related to Aphasia

Symptoms & Phenotypes for Aphasia

UMLS symptoms related to Aphasia:


back pain, cachexia, cyanosis, dyspnea, edema, fever, headache, icterus, other symptoms involving head and neck, pain, sciatica, seizures, signs and symptoms, signs and symptoms, digestive, syncope, tremor, vertigo, chronic pain, swelling, mass, or lump in head and neck, aprosodia, aphasic, sore throat, scanning speech, symptoms involving head and neck, other and unspecified speech disturbances, other symbolic dysfunction, vertigo/dizziness, hot flushes, sleeplessness, other speech disturbances, central nervous system signs and symptoms

MGI Mouse Phenotypes related to Aphasia:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.3 APOE APP C9orf72 GRIN2A GRN L1CAM
2 cellular MP:0005384 10.21 APOE APP C9orf72 GRN L1CAM LRRK2
3 nervous system MP:0003631 10.18 SLC20A2 SNCA APOE APP C9orf72 CHMP2B
4 immune system MP:0005387 10.16 APOE APP C9orf72 GRN LRRK2 MAPT
5 growth/size/body region MP:0005378 10.15 SNCA APOE APP C9orf72 L1CAM MAPT
6 mortality/aging MP:0010768 10.14 APOE APP C9orf72 GRN L1CAM LRRK2
7 hematopoietic system MP:0005397 10.13 APOE APP C9orf72 GRN LRRK2 MAPT
8 integument MP:0010771 10.09 MAPT PRNP PSEN1 SNCA APOE APP
9 no phenotypic analysis MP:0003012 9.97 APOE APP C9orf72 GRN L1CAM LRRK2
10 reproductive system MP:0005389 9.8 APOE APP GRN L1CAM PRNP PSEN1
11 skeleton MP:0005390 9.7 SNCA APOE L1CAM LRRK2 PRNP PSEN1
12 vision/eye MP:0005391 9.17 GRN L1CAM MAPT PRNP PSEN1 SLC20A2
13 taste/olfaction MP:0005394 9.13 APOE MAPT SNCA

Drugs & Therapeutics for Aphasia

Drugs for Aphasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 166)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
3
Benzocaine Approved Phase 4,Phase 3 1994-09-7, 94-09-7 2337
4
Donepezil Approved Phase 4 120014-06-4 3152
5 Piracetam Approved Phase 4,Phase 1 7491-74-9
6
Levodopa Approved Phase 4,Phase 2,Phase 3 59-92-7 6047
7
Citalopram Approved Phase 4 59729-33-8 2771
8
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
9
Amantadine Approved Phase 4,Phase 2,Phase 3 768-94-5 2130
10 tannic acid Approved, Nutraceutical Phase 4,Phase 3
11
Corticosterone Experimental Phase 4,Phase 1,Early Phase 1 50-22-6 5753
12 Antiparkinson Agents Phase 4,Phase 2,Phase 3
13 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1
14 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
15 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
16 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
17 Cholinergic Agents Phase 4,Phase 2
18 Cholinesterase Inhibitors Phase 4,Phase 2
19 Nootropic Agents Phase 4,Phase 2,Phase 1
20 Protective Agents Phase 4,Phase 1,Phase 2
21 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
22 Autonomic Agents Phase 4,Phase 2
23 Dopamine agonists Phase 4
24 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
25 Antidepressive Agents Phase 4,Phase 2,Phase 1
26 Antidepressive Agents, Second-Generation Phase 4
27 Psychotropic Drugs Phase 4,Phase 2,Phase 1
28
Serotonin Phase 4 50-67-9 5202
29 Serotonin Agents Phase 4
30 Serotonin Uptake Inhibitors Phase 4
31 Analgesics Phase 4,Phase 2,Phase 3
32 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
33 Anti-Inflammatory Agents Phase 4
34 Anti-Inflammatory Agents, Non-Steroidal Phase 4
35 Antipyretics Phase 4
36 Antirheumatic Agents Phase 4,Phase 2,Phase 3
37 Cyclooxygenase Inhibitors Phase 4
38 Fibrinolytic Agents Phase 4
39 Platelet Aggregation Inhibitors Phase 4
40 Fluorodeoxyglucose F18 Phase 4,Phase 2,Phase 1
41 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
42 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Pharmaceutical Solutions Phase 4
44
Carbidopa Approved Phase 2, Phase 3 28860-95-9 34359 38101
45
Miglustat Approved Phase 3,Phase 1 72599-27-0 51634
46
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
47
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
48
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
49
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
50
Topotecan Approved, Investigational Phase 3 119413-54-6, 123948-87-8 60700

Interventional clinical trials:

(show top 50) (show all 270)

id Name Status NCT ID Phase Drugs
1 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
2 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4 Ebixa;donepezil
3 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
4 Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial Completed NCT00196690 Phase 4 Donepezil
5 Dopaminergic Enhancement of Learning and Memory in Aphasia Completed NCT00102869 Phase 4 levodopa
6 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
7 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
8 Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke Completed NCT01762163 Phase 4 Qizhitongluo Capsule;Naoxintong Capsule;Aspirin Enteric-coated Tablets;placebo
9 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
10 A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke Terminated NCT01883011 Phase 4 Piracetam
11 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
12 Improvement of Language Disturbances After Stroke by Intensive Training and Electrical Brain Stimulation Unknown status NCT00822068 Phase 2, Phase 3
13 Augmenting Language Therapy for Aphasia: Levodopa Completed NCT01429077 Phase 2, Phase 3 levodopa/carbidopa;Placebo comparator
14 Action of Amantadine on Post-Stroke Aphasic Patients Completed NCT00821691 Phase 2, Phase 3 Amantadin;Placebo
15 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
16 Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
17 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
18 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
19 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer Completed NCT00390806 Phase 3 HYCAMTIN, oral capsules
20 Effects of MTS-r on Speech Production in Non-fluent Aphasia Post-ischemic Stroke Patients Recruiting NCT02241213 Phase 3
21 Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia Recruiting NCT00903266 Phase 3
22 Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window Recruiting NCT00826059 Phase 3
23 Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes Recruiting NCT02618577 Phase 3 Edoxaban;ASA
24 Use of Local Intraoperative Steroid in MIS TLIF Active, not recruiting NCT03308084 Phase 3 Methylprednisolone;Dexamethasone
25 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
26 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
27 Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Enrolling by invitation NCT02245568 Phase 3 TRx0237
28 Non-invasive Repetitive Paraorbital Alternating Current Stimulation Therapy for Aphasia Terminated NCT01277575 Phase 3
29 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS) Unknown status NCT01924702 Phase 2
30 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation Unknown status NCT01221779 Phase 2
31 Dextroamphetamine and tDCS to Improve the Fluency Unknown status NCT02514044 Phase 2 Dexedrine;Placebo
32 Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation Unknown status NCT02149160 Phase 2 FRM-0334;Placebo
33 Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia Completed NCT01300624 Phase 2
34 Treating Intention In Aphasia: Neuroplastic Substrates Completed NCT00567242 Phase 1, Phase 2
35 AERs in Aphasia: Severity and Improvement Completed NCT00013442 Phase 2
36 Psychosocial Wellbeing Following Stroke Completed NCT01912014 Phase 1, Phase 2
37 Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer's Disease Completed NCT00814697 Phase 2
38 Multimodal Treatment of Phonological Alexia: Behavioral & fMRI Outcomes Completed NCT00827268 Phase 1, Phase 2
39 A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia Completed NCT00416169 Phase 2 galantamine hydrobromide
40 Posturing Effects on Perception of Time and Perceptions of the Provider-Patient Interaction in the Emergency Department Completed NCT00170105 Phase 2
41 Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients Completed NCT00200538 Phase 2 memantine
42 Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. Completed NCT01890343 Phase 2 florbetapir 18F;18F-FDG
43 Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study Completed NCT00810095 Phase 2
44 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
45 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
46 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
47 tDCS and Aphasia Therapy in the Acute Phase After Stroke Recruiting NCT03297450 Phase 2
48 Evaluating Anodal tDCS Preceding Aphasia Therapy Recruiting NCT02249819 Phase 1, Phase 2
49 Dosage and Predictors of Naming Treatment Response in Aphasia Recruiting NCT02005016 Phase 1, Phase 2
50 Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study Recruiting NCT02540109 Phase 2

Search NIH Clinical Center for Aphasia

Genetic Tests for Aphasia

Genetic tests related to Aphasia:

id Genetic test Affiliating Genes
1 Aphasia 29

Anatomical Context for Aphasia

MalaCards organs/tissues related to Aphasia:

39
Brain, Testes, Cortex, Bone, Temporal Lobe, Eye, Prefrontal Cortex

Publications for Aphasia

Articles related to Aphasia:

(show top 50) (show all 1041)
id Title Authors Year
1
Cholinergic depletion and basal forebrain volume in primary progressive aphasia. ( 28018854 )
2017
2
Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia. ( 28515265 )
2017
3
Emotion detection deficits and changes in personality traits linked to loss of white matter integrity in primary progressive aphasia. ( 28879086 )
2017
4
Short Version of the Bilingual Aphasia Test in Malayalam. ( 28904451 )
2017
5
Constraint and multimodal approaches to therapy for chronic aphasia: A systematic review and meta-analysis. ( 28920522 )
2017
6
Globular glial tauopathy presenting as non-fluent/agrammatic variant primary progressive aphasia with chorea. ( 28923295 )
2017
7
Cerebellar induced differential polyglot aphasia: A neurolinguistic and fMRI study. ( 28917165 )
2017
8
Frequency of CNKSR2 mutation in the X-linked epilepsy-aphasia spectrum. ( 28098945 )
2017
9
Inner Speech's Relationship With Overt Speech in Poststroke Aphasia. ( 28885640 )
2017
10
Naming unique entities in the semantic variant of primary progressive aphasia and Alzheimer's disease: Towards a better understanding of the semantic impairment. ( 27939367 )
2017
11
Thinking on Treating Echolalia in Aphasia: Recommendations and Caveats for Future Research Directions. ( 28420974 )
2017
12
Priorities for closing the evidence-practice gaps in post-stroke aphasia rehabilitation: A scoping review. ( 28923500 )
2017
13
Comparing phoneme frequency, age of acquisition, and loss in aphasia: Implications for phonological universals. ( 28914137 )
2017
14
The Epilepsy-Aphasia Spectrum: From Landau-Kleffner Syndrome to Rolandic Epilepsy. ( 28628937 )
2017
15
Effectiveness of speech language therapy either alone or with add-on computer-based language therapy software (Malayalam version) for early post stroke aphasia: A feasibility study. ( 28870554 )
2017
16
[(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. ( 28912300 )
2017
17
Fidelity to a motivational interviewing intervention for those with post-stroke aphasia: a small-scale feasibility study. ( 28950785 )
2017
18
Aphasia As a Predictor of Stroke Outcome. ( 28929424 )
2017
19
The development and feasibility of an online aphasia group intervention and networking program - TeleGAIN. ( 28868932 )
2017
20
Investigating the origin of nonfluency in aphasia: AA path modeling approach to neuropsychology. ( 28866301 )
2017
21
Combined aphasia and apraxia of speech treatment (CAAST): Systematic replications in the development of a novel treatment. ( 28084854 )
2017
22
Effects of semantic weight on verb retrieval in individuals with aphasia: A different perspective. ( 28898710 )
2017
23
Semantic dementia, progressive non-fluent aphasia and their association with amyotrophic lateral sclerosis. ( 28554960 )
2017
24
Ictal conduction aphasia and ictal angular gyrus syndrome as rare manifestations of epilepsy: The importance of ictal testing during video-EEG monitoring. ( 28913167 )
2017
25
Temporal acoustic measures distinguish primary progressive apraxia of speech from primary progressive aphasia. ( 28187331 )
2017
26
Altered Structure and Intrinsic Functional Connectivity in Post-stroke Aphasia. ( 28921389 )
2017
27
A case of TREM2 mutation presenting with features of progressive non-fluent aphasia and without bone involvement. ( 28462591 )
2017
28
Functional activation independently contributes to naming ability and relates to lesion site in post-stroke aphasia. ( 28083891 )
2017
29
Sporadic Creutzfeldt-Jakob disease presenting with isolated progressive non-fluent aphasia in a young woman. ( 28444466 )
2017
30
The Nature of Error Consistency in Individuals With Acquired Apraxia of Speech and Aphasia. ( 28654943 )
2017
31
Reversible global aphasia as a side effect of quetiapine: a case report and literature review. ( 28894370 )
2017
32
Recovery of aphasia and change of injured arcuate fasciculus in the dominant hemisphere in stroke patients. ( 28946587 )
2017
33
A de novo loss-of-function GRIN2A mutation associated with childhood focal epilepsy and acquired epileptic aphasia. ( 28182669 )
2017
34
Use of tDCS in Aphasia Rehabilitation: A Systematic Review of the Behavioral Interventions Implemented With Noninvasive Brain Stimulation for Language Recovery. ( 27997958 )
2016
35
Benefits and Limitations of Computer Gesture Therapy for the Rehabilitation of Severe Aphasia. ( 27965554 )
2016
36
The Use of One or Three Semantic Associative Primes in Treating Anomia in Aphasia. ( 27997945 )
2016
37
WHEN WORDS FAIL. A SUMMARY OF APHASIA: INCORPORATING BACKGROUND MEMOIR ACCOUNTS. ( 27530025 )
2016
38
Brain Perfusion in Corticobasal Syndrome with Progressive Aphasia. ( 27195001 )
2016
39
The Role of the Cognitive Control System in Recovery from Bilingual Aphasia: A Multiple Single-Case fMRI Study. ( 27965899 )
2016
40
Subacute progressive aphasia: a rare presentation of Creutzfeldt-Jakob disease. ( 26872666 )
2016
41
Using principal component analysis to capture individual differences within a unified neuropsychological model of chronic post-stroke aphasia: Revealing the unique neural correlates of speech fluency, phonology and semantics. ( 27216359 )
2016
42
Cross-Linguistic Differences in a Picture-Description Task Between Korean- and English-Speaking Individuals With Aphasia. ( 27997955 )
2016
43
Lexical Ambiguity Resolution Using Discourse Contexts in Persons With and Without Aphasia. ( 27997957 )
2016
44
Am I looking at a cat or a dog? Gaze in the semantic variant of primary progressive aphasia is subject to excessive taxonomic capture. ( 26500393 )
2016
45
Increased inter-hemispheric resting-state functional connectivity in acute lacunar stroke patients with aphasia. ( 27942764 )
2016
46
Special Section: Language System Plasticity in Aphasia; Guest Editor: Roy Hamilton. ( 27567761 )
2016
47
Focal temporal pole atrophy and network degeneration in semantic variant primary progressive aphasia. ( 28040670 )
2016
48
Automated Proposition Density Analysis for Discourse in Aphasia. ( 27657850 )
2016
49
Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers. ( 27589533 )
2016
50
Direct current stimulation over the anterior temporal areas boosts semantic processing in primary progressive aphasia. ( 27553723 )
2016

Variations for Aphasia

Expression for Aphasia

Search GEO for disease gene expression data for Aphasia.

Pathways for Aphasia

GO Terms for Aphasia

Cellular components related to Aphasia according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 endosome GO:0005768 9.92 APP C9orf72 CHMP2B GRN LRRK2
2 cell surface GO:0009986 9.91 APP GRIN2A L1CAM PRNP PSEN1
3 synapse GO:0045202 9.9 APP GRIN2A LRRK2 SNCA
4 neuron projection GO:0043005 9.85 APP GRIN2A LRRK2 PSEN1
5 membrane raft GO:0045121 9.8 APP LRRK2 PRNP PSEN1
6 lysosome GO:0005764 9.77 C9orf72 CHMP2B GRN LRRK2 SNCA
7 synaptic vesicle GO:0008021 9.73 GRIN2A LRRK2 SNCA
8 dendrite GO:0030425 9.73 APOE L1CAM LRRK2 MAPT PRNP PSEN1
9 terminal bouton GO:0043195 9.65 APP LRRK2 SNCA
10 neuronal cell body GO:0043025 9.63 APOE L1CAM LRRK2 MAPT PSEN1 SNCA
11 rough endoplasmic reticulum GO:0005791 9.61 APP PSEN1 SNCA
12 smooth endoplasmic reticulum GO:0005790 9.59 APP PSEN1
13 nuclear outer membrane GO:0005640 9.58 PSEN1 SNCA
14 postsynapse GO:0098794 9.58 LRRK2 PRNP SNCA
15 ciliary rootlet GO:0035253 9.54 APP PSEN1
16 inclusion body GO:0016234 9.5 LRRK2 PRNP SNCA
17 axon GO:0030424 9.43 APP L1CAM LRRK2 MAPT PSEN1 SNCA
18 growth cone GO:0030426 9.1 APP L1CAM LRRK2 MAPT PSEN1 SNCA
19 plasma membrane GO:0005886 10.2 APOE APP CHMP2B GRIN2A L1CAM LRRK2
20 endoplasmic reticulum GO:0005783 10.05 APOE GRIN2A GRN LRRK2 PRNP PSEN1
21 Golgi apparatus GO:0005794 10.04 APOE APP LRRK2 PRNP PSEN1 SNCA

Biological processes related to Aphasia according to GeneCards Suite gene sharing:

(show all 48)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.88 APP LRRK2 PSEN1
2 negative regulation of neuron apoptotic process GO:0043524 9.86 APOE PSEN1 SNCA
3 cellular protein metabolic process GO:0044267 9.86 APOE APP PSEN1 SNCA
4 neuron projection development GO:0031175 9.85 APP L1CAM MAPT
5 autophagy GO:0006914 9.8 C9orf72 CHMP2B LRRK2 PSEN1
6 forebrain development GO:0030900 9.77 APP FOXP2 PSEN1
7 excitatory postsynaptic potential GO:0060079 9.77 GRIN2A LRRK2 SNCA
8 memory GO:0007613 9.74 GRIN2A MAPT PSEN1
9 regulation of autophagy GO:0010506 9.71 C9orf72 LRRK2 MAPT
10 regulation of synaptic transmission, glutamatergic GO:0051966 9.7 LRRK2 PSEN1
11 positive regulation of dendritic spine development GO:0060999 9.7 APOE PSEN1
12 regulation of canonical Wnt signaling pathway GO:0060828 9.7 LRRK2 PSEN1
13 negative regulation of neuron death GO:1901215 9.7 APOE LRRK2 SNCA
14 ionotropic glutamate receptor signaling pathway GO:0035235 9.69 APP GRIN2A
15 positive regulation of endocytosis GO:0045807 9.69 APOE SNCA
16 regulation of protein binding GO:0043393 9.69 APP PSEN1
17 regulation of neuron death GO:1901214 9.68 LRRK2 SNCA
18 regulation of neuronal synaptic plasticity GO:0048168 9.68 APOE SNCA
19 positive regulation of long-term synaptic potentiation GO:1900273 9.67 APP GRIN2A
20 microglial cell activation GO:0001774 9.67 MAPT SNCA
21 negative regulation of protein phosphorylation GO:0001933 9.67 LRRK2 PRNP PSEN1 SNCA
22 dopamine metabolic process GO:0042417 9.66 GRIN2A SNCA
23 positive regulation of receptor recycling GO:0001921 9.66 PSEN1 SNCA
24 cellular response to copper ion GO:0071280 9.65 PRNP SNCA
25 supramolecular fiber organization GO:0097435 9.65 MAPT SNCA
26 response to oxidative stress GO:0006979 9.65 APOE APP LRRK2 PRNP PSEN1
27 cellular copper ion homeostasis GO:0006878 9.64 APP PRNP
28 negative regulation of protein processing GO:0010955 9.64 LRRK2 PRNP
29 locomotion GO:0040011 9.63 GRIN2A PSEN1
30 amyloid precursor protein metabolic process GO:0042982 9.63 APOE PSEN1
31 amyloid fibril formation GO:1990000 9.62 APP MAPT
32 regulation of locomotion GO:0040012 9.62 LRRK2 SNCA
33 learning or memory GO:0007611 9.62 APP GRIN2A PRNP PSEN1
34 regulation of mitochondrial fission GO:0090140 9.61 LRRK2 MAPT
35 intracellular distribution of mitochondria GO:0048312 9.61 LRRK2 MAPT
36 negative regulation of long-term synaptic potentiation GO:1900272 9.55 APOE PRNP
37 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.51 APP PSEN1
38 astrocyte activation involved in immune response GO:0002265 9.48 APP PSEN1
39 positive regulation of neuron death GO:1901216 9.46 MAPT PRNP
40 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.43 APP PSEN1
41 cellular response to beta-amyloid GO:1904646 9.4 APP PSEN1
42 regulation of long-term neuronal synaptic plasticity GO:0048169 9.38 SNCA
43 locomotory exploration behavior GO:0035641 9.35 LRRK2
44 positive regulation of protein binding GO:0032092 9.28 LRRK2
45 negative regulation of beta-amyloid formation GO:1902430 9.27 APOE
46 synapse organization GO:0050808 8.92 APP L1CAM MAPT SNCA
47 astrocyte activation GO:0048143 8.85 MAPT
48 modulation of age-related behavioral decline GO:0090647 8.65 APP

Molecular functions related to Aphasia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.62 LRRK2 MAPT PRNP SNCA
2 identical protein binding GO:0042802 9.43 APOE APP LRRK2 MAPT PRNP SNCA
3 tau protein binding GO:0048156 9.37 APOE SNCA
4 cuprous ion binding GO:1903136 9.26 PRNP SNCA
5 lipoprotein particle binding GO:0071813 9.16 APOE MAPT
6 tubulin binding GO:0015631 8.8 LRRK2 MAPT PRNP
7 protein binding GO:0005515 10.22 APOE APP C9orf72 CHMP2B FOXP2 GRIN2A

Sources for Aphasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....